Immutep (NASDAQ:IMMP) Stock Price Passes Above Fifty Day Moving Average of $2.25

Immutep Limited (NASDAQ:IMMP)’s share price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.25 and traded as high as $2.34. Immutep shares last traded at $2.21, with a volume of 111,050 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird dropped their price objective on shares of Immutep from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, June 27th.

Immutep Trading Down 2.2 %

The company has a fifty day moving average of $2.26 and a two-hundred day moving average of $2.45.

Hedge Funds Weigh In On Immutep

Large investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in Immutep during the second quarter worth approximately $26,000. BNP Paribas Financial Markets boosted its holdings in shares of Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after buying an additional 4,700 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of Immutep during the 2nd quarter worth approximately $105,000. Virtu Financial LLC increased its stake in shares of Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 32,864 shares in the last quarter. Finally, Oracle Investment Management Inc. lifted its position in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after acquiring an additional 48,449 shares during the period. 2.32% of the stock is currently owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.